CONCORDBIO — Concord Biotech Share Price
Last trade - 00:00- IN₹162.50bn
- IN₹159.35bn
- IN₹10.17bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 37.83 | ||
| PEG Ratio (f) | 1.89 | ||
| EPS Growth (f) | 24.98% | ||
| Dividend Yield (f) | 0.63% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 10.45 | ||
| Price to Tang. Book | 10.45 | ||
| Price to Free Cashflow | 85.69 | ||
| Price to Sales | 15.25 | ||
| EV to EBITDA | 36.2 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 24.45% | ||
| Return on Equity | 22.16% | ||
| Operating Margin | 36.42% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 5,123.29 | 6,169.43 | 7,129.33 | 8,531.68 | 10,169.39 | 11,643.27 | 13,992.65 | 18.7% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +38.93 | -25.52 | +37.28 | +28.28 | +14.04 | +24.98 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Concord Biotech Limited is an India-based research and development driven biopharma company. The Company is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. The Company manufactures active pharmaceutical ingredients (API) through fermentation and semi-synthetic process and finished formulations. The Company’s offerings span both bio-pharmaceutical APIs and formulations across therapeutic areas like immunosuppressants oncology, anti-infectives nephrology, and critical care. Its portfolio also includes fermentation-based APIs in anti-bacterial, anti-fungal, and other therapeutic segments. Its API products include Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Sirolimus, Pimecrolimus, Voclosporin, Mupirocin, Mupirocin Calcium, Vancomycin Hydrochloride, Teicoplanin, Polymyxin B Sulfate, Fidaxomicin, Anidulafungin. Its API products under development include Daptomycin, Epirubicin, Idarubicin, and Pirarubicin.
Directors
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 23rd, 1984
- Public Since
- August 18th, 2023
- No. of Shareholders
- 83,803
- No. of Employees
- 1,377
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 104,616,204
- Address
- 10th Floor, AHMEDABAD, 380015
- Web
- https://www.concordbiotech.com/
- Phone
- +91 7968138700
- Auditors
- Deloitte Haskins & Sells LLP
Upcoming Events for CONCORDBIO
Similar to CONCORDBIO
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
As of Today at 20:02 UTC, shares in Concord Biotech are trading at IN₹1,588.00. This share price information is delayed by 15 minutes.
Shares in Concord Biotech last closed at IN₹1,588.00 and the price had moved by -2.96% over the past 365 days. In terms of relative price strength the Concord Biotech share price has underperformed the S&P BSE 100 Index by -8.58% over the past year.
The overall consensus recommendation for Concord Biotech is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Concord Biotech dividend yield is 0.55% based on the trailing twelve month period.
Last year, Concord Biotech paid a total dividend of IN₹8.75, and it currently has a trailing dividend yield of 0.55%. We do not have any data on when Concord Biotech is to next pay dividends.
We do not have data on when Concord Biotech is to next pay dividends. The historic dividend yield on Concord Biotech shares is currently 0.55%.
To buy shares in Concord Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹1,588.00, shares in Concord Biotech had a market capitalisation of IN₹162.50bn.
Here are the trading details for Concord Biotech:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: CONCORDBIO
Based on an overall assessment of its quality, value and momentum Concord Biotech is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Concord Biotech is IN₹1,918.68. That is 20.82% above the last closing price of IN₹1,588.00.
Analysts covering Concord Biotech currently have a consensus Earnings Per Share (EPS) forecast of IN₹33.59 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Concord Biotech. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -10.28%.
As of the last closing price of IN₹1,588.00, shares in Concord Biotech were trading -15.83% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Concord Biotech PE ratio based on its reported earnings over the past 12 months is 37.83. The shares last closed at IN₹1,588.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Concord Biotech's directors